Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Neurological Effects of EryDex in Subjects With Ataxia Telangiectasia (NEAT)

Next Previous
Trial Profile

A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Neurological Effects of EryDex in Subjects With Ataxia Telangiectasia (NEAT)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary)
  • Indications Ataxia telangiectasia
  • Focus Registrational; Therapeutic Use
  • Acronyms the NEAT Trial
  • Sponsors EryDel

Most Recent Events

  • 25 Jun 2025 According to a Quince Therapeutics media release, will provide an overview of this phase 3 trial at the upcoming 2025 A-T Clinical Research Conference organized by the A-T Society taking place June 25-27, 2025 at Loughborough University in the U.K.
  • 18 Jun 2025 According to a Quince Therapeutics media release, company intends to use the net proceeds of this offering for funding the ongoing enrollment of the Company's pivotal Phase 3 NEAT clinical trial in A-T.
  • 18 Jun 2025 According to a Quince Therapeutics media release, company announced the closing of its previously announced sale and issuance to certain institutional and accredited investors, of its common stock, and accompanying common warrants that resulted in approximately $11.5 million in upfront proceeds and potential additional proceeds of up to $10.4 million if the accompanying Warrants are exercised in full for cash, before deducting placement agent fees and other private placement expenses.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top